<DOC>
	<DOCNO>NCT00176540</DOCNO>
	<brief_summary>RATIONALE : Dextromethorphan may help relieve fatigue patient cancer . PURPOSE : This clinical trial study well dextromethorphan work treat patient fatigue caused cancer .</brief_summary>
	<brief_title>Dextromethorphan Treating Patients With Fatigue Caused Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess effect dextromethorphan hydrobromide patient cancer-related fatigue . Secondary - Correlate change cancer-related fatigue level plasma homocysteine versus red blood cell folate . OUTLINE : This multicenter , open-label , pilot study . Patients receive oral dextromethorphan hydrobromide 3 time day day 1-7 . Treatment repeat weekly 3 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis malignancy Must undergo active treatment malignancy may include hormonal therapy ( e.g. , tamoxifen citrate leuprolide acetate ) , radiotherapy alone Fatigue score â‰¥ 4 verbal analogue scale 0 10 No untreated cancerrelated anemia PATIENT CHARACTERISTICS : Hemoglobin &gt; 10 g/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able swallow pills No know allergy dextromethorphan hydrobromide No patient know phenotypically poor metabolizers CYP2D6 No untreated hypothyroidism PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior singledose inhibitor ( e.g. , ranitidine cimetidine ) hypersensitivity prophylaxis allow Erythropoietic growth factor therapy &gt; 8 week duration allow No concurrent CYP2D6 inducer inhibitors No concurrent monoamine oxidase inhibitors No concurrent medication contain dextromethorphan hydrobromide No concurrent overthecounter medication , herbal product , vitamin , food supplement , type special product unless permission continue use obtain Principal Investigator No concurrent anticancer investigational agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>fatigue</keyword>
</DOC>